



FOR IMMEDIATE RELEASE

July 17, 2019

Contact: Jacqueline Clark, [jacqueline@sqcomms.com](mailto:jacqueline@sqcomms.com)

Charlie Patterson, [charlie@sqcomms.com](mailto:charlie@sqcomms.com)

**George Hodgin, CEO of Biopharmaceutical Research Company, praises bill to reduce barriers to medicinal cannabis research**

**MONTEREY, CA** - On July 17, 2019 US Representatives Earl Blumenauer (D-OR), Andy Harris, M.D. (R-MD), Zoe Lofgren (D-CA), H. Morgan Griffith (R-VA), Debbie Dingell (D-MI) and Rob Bishop (R-UT) introduced the Medical Marijuana Research Act of 2019. This legislation facilitates cannabis research by removing barriers preventing the growth and distribution of cannabis strictly for research purposes, and creates a new registration process to facilitate medicinal cannabis research.

George Hodgin, former Navy SEAL and founder and CEO of Biopharmaceutical Research Company (BRC), issued the following statement praising the legislation:

“For three years, I have waited for approval from the Drug Enforcement Administration to grow cannabis strictly for government-sanctioned research purposes. I have built a facility in compliance with federal regulations and hired a team ready to work, but we are stalled by federal bureaucracy.

With thorough research and testing, patients across America could potentially benefit from medicinal cannabis, including many of my fellow veterans who struggle with chronic pain and post-traumatic stress. Lawmakers will also benefit as they consider policy to address the possible negative health consequences that can only be adequately understood through advanced research. The Medical Marijuana Research Act is an important step toward removing federal barriers to cannabis research, and I urge the Judiciary and Energy & Commerce Committees to promptly advance this bill.”

*George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.*

**About Biopharmaceutical Research Company**

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world. BRC also conducts federally compliant cannabis-specific analytical activities.

###